GRI Bio Inc
NASDAQ:GRI
GRI Bio Inc
NASDAQ:GRI
Price:
2.28
USD
-0.87%
Market Closed
Market Cap:
$3.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
GRI Bio Inc
NASDAQ:GRI
|
US |
|
C
|
Changjiang & Jinggong Steel Building Group Co Ltd
SSE:600496
|
CN |
|
Neonode Inc
NASDAQ:NEON
|
SE |
|
C
|
Carnarvon Energy Ltd
ASX:CVN
|
AU |
|
Hyundai Motor Co
KRX:005380
|
KR |
|
Yellow Brick Road Holdings Ltd
ASX:YBR
|
AU |
|
MBB SE
XETRA:MBB
|
DE |
|
S
|
Segar Kumala Indonesia Tbk PT
IDX:BUAH
|
ID |
|
V
|
Vifor Pharma AG
SIX:VIFN
|
CH |
|
Dole PLC
NYSE:DOLE
|
IE |
|
Kanabo Group PLC
LSE:KNB
|
UK |
|
Sino Land Co Ltd
HKEX:83
|
HK |
|
Wrkr Ltd
ASX:WRK
|
AU |
|
S
|
Sai Gon Mien Trung Beer JSC
VN:SMB
|
VN |
|
L
|
Life Science REIT PLC
LSE:LABS
|
UK |
Multiples-Based Value
The Multiples-Based Value of one
GRI
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 2.28 USD,
GRI Bio Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GRI Multiples-Based Value
LOCKED
Multiples Across Competitors
GRI Competitors Multiples
GRI Bio Inc Competitors
GRI Bio Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
GRI Bio Inc
NASDAQ:GRI
|
3.3m USD | 0 | -0.3 | 0.4 | 0.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
